PRE-CONFERENCE WORKSHOP*

8:45 - 11:00 MAXIMIZING PORTFOLIO VALUE IN A TIME OF INCREASINGLY CONSTRAINED RESOURCES

How companies can assess economic value, risk and potential of life sciences assets and use them to maximize portfolio value within constrained resources
Life sciences assets including R&D, show high levels of uncertainty and decision flexibility. They also interact with each other in a portfolio. As such, traditional financial analyses have been ineffective in assessing economic value of them. At the portfolio level, interactions between assets make it difficult to assess risk and overall potential. Based on the recently published text book entitled, "Decision Options: The Art and Science of Making Decisions," this workshop demonstrates how companies can use market based valuations to better manage their portfolios.

• How to assess a market based economic value for life sciences assets including R&D, licenses and patents?
• How to develop a portfolio management process that maximizes value while providing guidance on risk and overall potential?
• How to make selection, design and portfolio management decisions within R&D

Workshop Leaders:

Mr. Gill Eapen, MS, MBA, CFA, Managing Principal, Decision Options, LLC

Jennifer Miller, Executive Director, Pharmaceutical Sciences, Pfizer Inc.

* Separate registration is required.